Vanda Pharmaceuticals Inc. (VNDA) Q3 2026 Earnings Call Transcript

Vanda Pharmaceuticals Inc. (VNDA) Q3 2026 Earnings Call Transcript

Seeking Alpha • 17 hours ago

Vanda Pharmaceuticals Q3 Earnings Call Highlights

Vanda Pharmaceuticals NASDAQ: VNDA reported third-quarter revenue growth of 24% from a year earlier, supported by higher Fanapt sales and a sharp sequential increase in HETLIOZ revenue tied partly to specialty-pharmacy purchasing and shipment timing. The company also said operating expenses declined 18% from the second quarter as certain late-stage development and launch-preparation activities concluded.

MarketBeat • a day ago

Vanda Pharmaceuticals Reports Third Quarter 2026 Financial Results

Q3 2026 Total Revenues increased 24% to $69.8 million compared to Q3 2025 and 38% compared to Q2 2026 Q3 2026 Total Operating Expenses decreased by 18% to $93.3 million compared to Q2 2026 Announced positive results from the Phase III study of NEREUS™ for prevention of GLP-1-induced vomiting NEREUS™ for prevention of vomiting induced by motion became commercially available in Q2 2026 BYSANTI™ commercial launch expected in Q4 2026 Quimilza™ BLA for GPP under review by the FDA; PDUFA target action date of December 12, 2026 WASHINGTON, Oct. 28, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced financial and operational results for the third quarter ended September 30, 2026.  "We are pleased with the strong revenue growth in the third quarter, increasing 24% year-over-year, driven by continued Fanapt momentum and the early contribution from our NEREUS commercial launch, while operating expenses decreased 18% compared to the second quarter as key Phase III and launch-preparation activities conclude," said Mihael H.

PRNewsWire • Oct 28, 2026

Vanda Pharmaceuticals (VNDA) Reports Q3 Loss, Tops Revenue Estimates

Vanda Pharmaceuticals (VNDA) came out with a quarterly loss of $0.37 per share versus the Zacks Consensus Estimate of a loss of $0.72. This compares to a loss of $0.38 per share a year ago.

Zacks Investment Research • Oct 28, 2026

Vanda Pharmaceuticals Targets Major GLP-1 Market Challenge with Positive Trial Outcomes

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) released results from its Phase 3 trial evaluating Nereus, an oral therapy aimed at preventing vomiting associated with GLP-1 receptor agonist treatments.

Benzinga • Oct 27, 2026

Vanda Pharmaceuticals Announces Positive Results from Study 3601 of NEREUS™ (tradipitant) for Prevention of GLP-1-Induced Vomiting

NEREUS™ significantly reduced semaglutide induced vomiting including frequent multi-day and extreme vomiting Key Results Any vomiting (primary) 43.0% (61/142) vs 58.5% (96/164) placebo (p=0.006); 27% relative reduction Vomiting + severe nausea (key secondary): 33.1% (47/142) vs 50.6% (83/164) (p=0.002); 35% relative reduction Frequent multi-day vomiting (>2 episodes on more than one day): 6.3% (9/142) vs 15.9% (26/164) (p=0.008); 60% relative reduction Extreme vomiting (>10 total episodes): 2.8% (4/142) vs 14.6% (24/164) (p=0.0003); 81% relative reduction WASHINGTON, Oct. 27, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) today announced positive results from Study 3601 (VP-VLY-686-3601), a Phase III randomized, placebo-controlled study evaluating NEREUS™ (tradipitant), an oral neurokinin-1 (NK-1) receptor antagonist, for the prevention of vomiting associated with GLP-1 receptor agonist therapy. The study showed significant reduction in overall vomiting episodes (27% p=0.006 as well as reduction of frequent (60% p=0.008) and extreme vomiting (81% p=0.0003) episodes.

PRNewsWire • Oct 27, 2026

Vanda Pharmaceuticals to Announce Third Quarter 2026 Financial Results on October 28, 2026

Conference Call and Webcast to Follow WASHINGTON, Oct. 21, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced it will release results for the third quarter 2026 on Wednesday, October 28, 2026, after the market closes.   Vanda will host a conference call at 4:30 PM ET on Wednesday, October 28, 2026, during which management will discuss the third quarter 2026 financial results and other corporate activities.

PRNewsWire • Oct 21, 2026

Vanda Pharmaceuticals Says Experimental Anxiety Treatment Misses Primary Endpoint

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) on Wednesday shared an update regarding its clinical development pipeline.

Benzinga • Oct 15, 2026

Vanda says anxiety drug failed main goal of late-stage study, puts program on hold

Vanda Pharmaceuticals said on Wednesday its experimental drug for social anxiety disorder ​failed the main goal of a ‌late-stage study, prompting the company to put the program on hold pending further analysis of ​the data.

Reuters • Oct 14, 2026

Vanda Pharmaceuticals Provides Update on VQW-765 Clinical Development Program

Phase III clinical study of VQW-765 in adults with social anxiety disorder did not meet its primary endpoint Consistent with prior studies, VQW-765 was safe and well tolerated WASHINGTON, Oct. 14, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today provided an update on its clinical development program for VQW-765, a novel small molecule alpha 7 nicotinic acetylcholine receptor (α7-nAChR) partial agonist. Vanda's Phase III clinical study, VP-VQW-765-3201 (Study 3201), which evaluated VQW-765 for the on-demand treatment of acute anxiety in adults with social anxiety disorder, did not meet its primary endpoint.

PRNewsWire • Oct 14, 2026